J&J nears the sale of its Ortho clinical Dx division, and other big news from the holidays

FierceMedicalDevices resumes Monday-Friday email newsletter publication today after a nice holiday breather. But we kept a close eye on med tech news in the interim. Below, we've provided links to those stories you may have missed while you were away. Click away and catch up, and, as always, thanks for reading.

- Myriad ($MYGN) braces for a direct hit with CMS set to slash BRCA Dx test payments. Story

- Abbott ($ABT) forks over $5.5M to settle physician kickback allegations. Story

- MC10 grabs $19.8M more to advance stretchable sensors for med tech. Story

- Intuitive Surgical's ($ISRG) robot surgery injuries went unreported for years, report says. Story

- Stryker ($SYK) director (and founder's granddaughter) sells a pile of shares. Story

- Boston Scientific ($BSX) plots a major China expansion in the months to come. Story

- Report: J&J ($JNJ) wants Carlyle to snatch up its Ortho Clinical Diagnostics arm. Story

- Mederi draws $18.5M Series B to expand reach of GI treatment devices. Story

- Intact raises $4.7M to further its PAD device work. Story

- Carmat's (so far) successful human artificial heart transplant shoots stock higher. Story

-- Mark Hollmer (email | Twitter)

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.